NCT00005091View on ClinicalTrials.gov

DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 1999

Study Completion Date

August 31, 2003

Conditions
Lung Cancer
Interventions
DRUG

exatecan mesylate

Trial Locations (6)

FIN-0-0029

Helsinki University Central Hospital, Helsinki

D-69126

Thoraxklinik Rohrbach, Heidelberg

I-40139

Ospedale Bellaria, Bologna

1117 MB

Academisch Ziekenhuis der Vrije Universiteit, Amsterdam

M20 4BX

Christie Hospital N.H.S. Trust, Manchester

0X3 7LJ

Oxford Radcliffe Hospital, Oxford

Sponsors
All Listed Sponsors
lead

Daiichi Pharmaceuticals

INDUSTRY

NCT00005091 - DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter